Search results
Results from the WOW.Com Content Network
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source , are explained in Nomenclature of monoclonal antibodies .
Its name is composed of the components olara-t-u-mab. This shows that the drug is a human monoclonal antibody acting against tumors. [34] The name of benralizumab, a drug designed for the treatment of asthma, has the components benra-li-zu-mab, marking it as a humanized antibody acting on the immune system. [42]
Pages in category "Drugs that are a monoclonal antibody" The following 200 pages are in this category, out of approximately 482 total. This list may not reflect recent changes .
Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs.In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are international nonproprietary names (INNs); and trade names, which are brand names. [1]
A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell.
Leqembi, known generically as lecanemab, is a monoclonal antibody that works to remove a protein called amyloid from the brain. It received full Food and Drug Administration approval in July.
The first FDA-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab), in 1986. This drug found use in solid organ transplant recipients who became steroid resistant. [39] Hundreds of therapies are undergoing clinical trials. Most are concerned with immunological and ...
In 2020, AbbVie acquired the rights to I-Mab's antibody-based drug candidates, including lemzoparlimab, outside China for $180 million upfront payment and additional $1.74 billion in milestone ...